Results 41 to 50 of about 755,616 (163)

Aminopyrazole Carboxamide Bruton’s Tyrosine Kinase Inhibitors. Irreversible to Reversible Covalent Reactive Group Tuning

open access: yes, 2018
Potent covalent inhibitors of Bruton’s tyrosine kinase (BTK) based on an aminopyrazole carboxamide scaffold have been identified. Compared to acrylamide-based covalent reactive groups leading to irreversible protein adducts, cyanamide-based reversible ...
Zhao-Kui Wan (2004907)   +31 more
core   +1 more source

Screening and Characterization of Allosteric Small Molecules Targeting Bruton’s Tyrosine Kinase

open access: yes, 2023
Bruton’s Tyrosine Kinase (BTK) is a nonreceptor tyrosine kinase that belongs to the TEC family. Mutations in the BTK gene cause X-linked agammaglobulinemia (XLA) leading to an arrest in B-cell development.
Joseph Serrenho (17628618)   +6 more
core   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonists in Multiple Sclerosis: A Topical Narrative Review

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT The glucagon‐like peptide‐1 (GLP‐1) receptor agonists (RAs) are a relatively new class of drugs that were initially approved by the US Food and Drug Administration to improve glycemic control in patients with type 2 diabetes mellitus and, subsequently, weight reduction in patients with obesity.
Audrey Y. Chang, Farrah J. Mateen
wiley   +1 more source

Single‐Cell Transcriptomic Profiling Identifies B Cell‐Intrinsic Dysregulation of Sphingolipid Biosynthesis and Could Be Improved by Inhibiting UGCG in Primary Immune Thrombocytopenia

open access: yesAdvanced Science, EarlyView.
This study generates the single‐cell atlas of pathogenic B‐cell subset Bc‐5 in ITP. It identifies RUNX3 as a key survival regulator and uncovers sphingolipid‐driven metabolic reprogramming, validating UGCG inhibition as a therapeutic candidate and building a valuable resource for ITP mechanistic and therapeutic exploration.
Dongmei Luo   +10 more
wiley   +1 more source

Bruton’s tyrosine kinase regulates apoptosis and JNK/SAPK kinase activity

open access: yes, 1997
Mast cells derived from Bruton’s tyrosine kinase (Btk)-defective xid or btk null mice showed greater expansion in culture containing interleukin-3 (IL-3) than those from wild-type ( wt ) mice.
Kitamura, Toshio   +21 more
core   +1 more source

Disseminated fungal infection in a patient receiving zanubrutinib

open access: yesClinical Case Reports, 2023
Key Clinical Message We report a case of fatal disseminated aspergillosis in the setting of administration of zanubrutinib, a second‐generation Bruton's tyrosine kinase inhibitor thought to have a lower rate of immunosuppression‐related side effects.
Madalyn Walsh   +3 more
doaj   +1 more source

Chromosomal Abnormalities, Drug Sensitivity and Resistance in Hematological Malignancies: A Comprehensive Overview by the Francophone Group of Hematological Cytogenetics (GFCH)

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Chromosomal abnormalities have a major clinical impact on hematological malignancies, particularly with regard to treatment strategies. To preserve and consolidate fundamental knowledge in this rapidly evolving field, the Francophone Group of Hematological Cytogenetics (Groupe Francophone de Cytogénétique Hématologique, GFCH) conducted a ...
Florence Nguyen‐Khac   +16 more
wiley   +1 more source

Correction to: Role of Bruton’s tyrosine kinase in B cells and malignancies

open access: yesMolecular Cancer, 2019
Following publication of the original article [1], the authors reported an error in Table 1.
Simar Pal Singh   +2 more
doaj   +1 more source

The Bruton’s Tyrosine Kinase Inhibitor Ibrutinib Impairs the Vascular Development of Zebrafish Larvae

open access: yesFrontiers in Pharmacology, 2021
Ibrutinib is an orally bioavailable, irreversible selective Bruton’s tyrosine kinase inhibitor that has demonstrated impressive therapeutic effects in patients with B cell malignancies.
Kun Wang, Qiushi Xu, Hanbing Zhong
doaj   +1 more source

Final Analysis of the BRUIN Phase 1/2 Study Assessing the Safety and Efficacy of Pirtobrutinib Monotherapy in Patients With MCL

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Pirtobrutinib, a highly selective, non‐covalent Bruton tyrosine kinase inhibitor (BTKi) previously demonstrated durable efficacy and tolerable safety following covalent (c) BTKi therapy in heavily pretreated relapsed/refractory (R/R) mantle cell lymphoma (MCL).
Michael L. Wang   +36 more
wiley   +1 more source

Home - About - Disclaimer - Privacy